🇺🇸

US SEC Filing Intelligence

· daily

Contract Option Exercises — March 01, 2026

Lockheed Martin Services secures a $20.65B cost-plus award fee contract with DOE for Y-12 plant management through Feb 2027, signaling strong revenue visibility in government-owned contractor-operated (GOCO) facilities. Despite zero outlays to date, the fully funded structure and full competition award highlight stability in facilities support services. Investors should monitor DOE budgets for execution risks amid this outsized single-contract concentration.

1 total filings
· daily

All DOE Contracts — March 01, 2026

A single $20.65B DOE contract for Lockheed Martin underscores exceptional long-term revenue stability in Y-12 plant management through 2027, providing high-confidence bullish signal for the company amid full and open competition. No outlays despite 43-year history flags execution risks tied to DOE budgets, warranting caution on near-term cash flows. Fully funded structure and follow-on potential position Lockheed as a prime watch item in facilities support services.

1 total filings
· daily

High-Value Federal Grants ($5M+) — March 01, 2026

A single massive $20.65B cost-plus contract awarded to Lockheed Martin Services, LLC for Y-12 plant management through Feb 2027 signals strong revenue visibility in DOE facilities operations. Despite zero outlays to date, the fully funded structure and full/open competition award underscore long-term stability for Lockheed Martin in NAICS 561210 services. Investors should monitor DOE budget execution amid funding risks, with potential follow-on opportunities post-2027.

1 total filings
· daily

DOE Energy Grants — March 01, 2026

A single massive $20.65B DOE contract awarded to Lockheed Martin Services underscores long-term revenue stability for Y-12 plant management through Feb 2027, signaling bullish commitment to GOCO facilities operations amid full competition. No outlays despite 2026 period highlight execution risks tied to DOE budgeting. Investors should prioritize Lockheed Martin for defense/energy services exposure with potential follow-on beyond 2027.

1 total filings
· daily

NME Blockbuster Approvals — February 28, 2026

FDA approval of LOARGYS (PEGZILARGINASE-NBLN) on Feb 23, 2026, delivers a bullish catalyst for Immedica Pharma AB via original NME with Priority Review and Orphan Drug status, enabling premium pricing and exclusivity. This isolated event in the NME Blockbuster stream signals strong regulatory momentum but lacks indication details for market sizing. Investors should prioritize monitoring commercial launch for revenue potential amid unknown competition.

1 total filings
· daily

Biotech Small-Cap Approvals — February 28, 2026

This one-day period saw 12 neutral generic ANDA approvals out of 13 records, concentrated in Brivaracetam (4 sponsors), Liraglutide (2), and Sitagliptin Phosphate (2), signaling broad generic portfolio expansions for small-cap sponsors but routine pricing pressure ahead. The sole bullish outlier is Immedica Pharma AB's priority-reviewed NME Orphan Drug BLA for LOARGYS (PEGZILARGINASE-NBLN), offering premium positioning via exclusivity. Investors should prioritize Immedica for growth while monitoring generic erosion in epilepsy and diabetes segments.

13 total filings
· daily

Orphan Drug Approvals — February 28, 2026

Immedica Pharma AB's FDA approval of LOARGYS (PEGZILARGINASE-NBLN) via priority review for an original NME orphan drug represents the period's sole bullish catalyst, enabling near-term commercial launch with exclusivity and premium pricing. Two identical neutral signals for Array Biopharma's Encorafenib highlight data redundancy and lack of material developments, signaling portfolio stability but no upside. Overall, sparse activity underscores selective orphan drug opportunities amid neutral biotech backdrop.

3 total filings
· daily

New Drug Approvals (Original) — February 28, 2026

This one-day period (approvals Feb 23-24, 2026) features 12 routine ANDA generic approvals, mostly from Indian sponsors, concentrated in Brivaracetam (4 approvals), Liraglutide/Sitagliptin Phosphate (2 each), signaling imminent pricing erosion in these molecules. The standout event is Immedica Pharma AB's priority-reviewed Orphan NME BLA approval for PEGZILARGINASE-NBLN, a rare bullish catalyst amid generic dominance. Neutral implications dominate, with no bearish signals but elevated competitive risks for crowded generics.

13 total filings
· daily

Defense Manufacturing Contracts — February 28, 2026

Two major defense manufacturing contracts totaling $1.57B in obligations signal bullish backlog growth for Austal USA (Austal Limited) and Lockheed Martin, with combined potential value exceeding $3.7B via options. Long-duration commitments (to 2030 and 2033) provide revenue visibility amid execution risks from low outlays ($61M for Austal, 64% for Lockheed) and cost structures. Investors should prioritize monitoring option exercises for uplift in shipbuilding and space sectors.

2 total filings
· daily

DHS Homeland Security Contracts — February 28, 2026

DHS contracts for Feb 28, 2026, total $1.47B, dominated by Austal USA's $1.23B Coast Guard OPC shipbuilding award (84% of value, options to $3.3B), signaling robust fleet modernization demand. Granite's $169M CBP border barrier contract adds infrastructure momentum, while DDL Omni's $72M legacy engineering deal remains neutral with $0 outlay post-2022 end. Aggregate low outlays (4% of obligations) highlight multi-year revenue potential offset by execution risks in fixed-price structures.

3 total filings
· daily

VA Healthcare & Services Contracts — February 28, 2026

Two high-value VA contracts totaling $328.6M awarded to diverse-owned firms (veteran and minority) via full/open competition signal strong demand for medical disability exams and IT enterprise testing, both rated bullish for revenue potential. VES shows near-complete cash realization ($164M outlayed of $166M), while PSI offers multi-year upside to 2025 ($162M obligation, $164M base+options). Investors should prioritize VA services exposure amid robust funding utilization patterns.

2 total filings
· daily

NASA & Space Contracts Intelligence — February 28, 2026

Lockheed Martin secured a $347.8M NASA contract (potential $396.5M with options) for the Lucy mission to Jupiter's Trojan asteroids, spanning 2017-2033, delivering long-term revenue visibility in space vehicle manufacturing. This bullish signal underscores NASA's sustained deep-space exploration funding amid a single-contract period. Investors should monitor execution risks over the extended timeline and option exercises for full value realization.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — February 28, 2026

Two firm-fixed-price contracts totaling $367M awarded to Whiting-Turner ($198M GSA office consolidation) and Granite ($169M DHS border infrastructure) signal robust federal construction spending under NAICS 236220. Multi-year backlogs (to 2026-2028) provide revenue visibility, though low outlays ($0 and $20M) indicate early stages. Bullish for targeted firms amid sector tailwinds, with shared execution risks warranting close monitoring.

2 total filings
· daily

Federal Professional Services Contracts — February 28, 2026

Three federal professional services contracts total $482M obligations, adding backlog visibility primarily in engineering (NAICS 541330) for space and coast guard, plus health consulting. Booz Allen Hamilton's bullish $177M award (up to $531M options) stands out for space systems support through 2028 potential. Low outlays ($0-3.4M across all) flag execution delays, while $1.34B combined options ceiling offers material upside if exercised.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — February 28, 2026

A single $162M VA IT contract to Planned Systems International Inc signals bullish revenue potential through 2025-06-13, with base + options reaching $164M via Time & Materials structure reducing execution risk. Low $7.2M outlay to date highlights early-stage execution dependency on option exercises amid T&M audit vulnerabilities. Minority-owned IT firms demonstrate competitive edge in open VA procurements, warranting sector monitoring.

1 total filings
· daily

New Federal Contractors — February 28, 2026

This batch adds $3.3B in federal contract obligations, predominantly bullish (9/12), bolstering backlogs in defense shipbuilding, space, healthcare services, and construction with long-term visibility to 2033. Key upside from unexercised options exceeding $4B potential across top awards (e.g., Austal $3.3B ceiling, Booz Allen $531M). Low average outlays (~10-20% of obligations) signal early-stage execution risks but stable revenue ramps for primes like Austal, Lockheed, and Noridian.

12 total filings
· daily

Significant Contract Modifications ($10M+) — February 28, 2026

These 12 significant contract modifications totaling $3.3B signal strong federal spending momentum in defense shipbuilding, healthcare services, and infrastructure, with 9 bullish awards providing multi-year revenue backlogs for primes like Austal USA ($1.2B OPCs) and Lockheed Martin ($348M Lucy mission). Low average outlays (~15% of obligations) across early-stage contracts highlight execution risks but also substantial upside from $1B+ in unexercised options. Institutional investors should prioritize defense and VA-related contractors for stable cash flows through 2033, monitoring funding ramps and option exercises.

12 total filings